Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phasebio Pharmaceuticals (PHASQ)
OTHER OTC:PHASQ
Phasebio Pharmaceuticals (PHASQ) Stock Price & Analysis
691 Followers
PHASQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.02
Volume501.00
Average Volume (3M)N/A
Market Cap
$50.00
Enterprise Value-$2.86M
Total Cash (Recent Filing)$7.80M
Total Debt (Recent Filing)$4.94M
Price to Earnings (P/E)―
Beta292.80
Next Earnings
Aug 15, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding49,858,116
10 Day Avg. Volume510
30 Day Avg. VolumeN/A
Standard Deviation0.85
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.49
Enterprise Value/Gross Profit-0.26
Enterprise Value/Ebitda0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
30.55%
Insiders
0.00% Mutual Funds
0.77% Other Institutional Investors
68.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PHASQ FAQ
What was Phasebio Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Phasebio Pharmaceuticals’s market cap?
Currently, no data Available
When is Phasebio Pharmaceuticals’s upcoming earnings report date?
Phasebio Pharmaceuticals’s upcoming earnings report date is Aug 15, 2023 which is 339 days ago.
How were Phasebio Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Phasebio Pharmaceuticals overvalued?
According to Wall Street analysts Phasebio Pharmaceuticals’s price is currently Overvalued.
Does Phasebio Pharmaceuticals pay dividends?
Phasebio Pharmaceuticals does not currently pay dividends.
What is Phasebio Pharmaceuticals’s EPS estimate?
Phasebio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Phasebio Pharmaceuticals have?
Phasebio Pharmaceuticals has 49,858,116 shares outstanding.
What happened to Phasebio Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Phasebio Pharmaceuticals?
Among the largest hedge funds holding Phasebio Pharmaceuticals’s share is RA Capital Management. It holds Phasebio Pharmaceuticals’s shares valued at N/A.
---
Phasebio Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Phasebio Pharmaceuticals
PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
---
ACADIA Pharmaceuticals
―
Adverum Biotechnologies
―
Alnylam Pharma
―
Arvinas Holding Company
―
---